Immuron Limited · ASX:IMC
Immuron — Emerging Growth Conference (October 2025)
14 slides from Immuron's conference presentation, Oct 23, 2025
Slide 1: Emerging Growth Conference
EMERGING GROWTH CONFERENCE 22 OCTOBER 2025 S teve n Lyde a m ore - C EO NASDAQ: IMRN ASX: IMC
Slide 2: Safe Harbor Statement
Certain statements made in this presentation are forward - looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as ” anticipates,” “expects,” “intends,” “plans,” “believes,” ” seeks,” “estimates,” “guidance” and s imilar expressions are intended t
Slide 3: Results, Upcoming Milestones & Outlook Executive Summary
3 Q1, FY26 Global Sales Revenue of A$2.0 million up 34% on Q1, FY25 ProIBS® to be launched in Australia in October 2025 Clinical Development Travelan® IMM - 124E: 1H 2026: End of Phase 2 FDA meeting (Phase 2; n=60) IMM - 529 (CDI): Immuron anticipates FDA approval of IND in December 2025 Results, Up
Slide 4: 1. Financial & Operational Highlights
1. FINANCIAL & OPERATIONAL HIGHLIGHTS
Slide 5: FY25 Financial Summary
5 FY25 Financial Summary Global Sales Revenue $7.3m Up 49% Australian Sales Revenue $5.3m Up 40% North American Sales Revenue $2.0m Up 76% Gross Profit Margin 65.4% EBITDA (ex - R&D) 1 $(3.1)m $2.1m improvement Cash + Term Deposit $5.9m (excludes A$2.8m raised from the US placement) 2 1 ex - R&D : a
Slide 6: Immuron: Australian integrated biopharmaceutical company
6 Immuron Ltd is an Australian integrated biopharmaceutical company with global scale, focused on developing, and commercialising, oral immunotherapeutic for the treatment of gut mediated diseases Immuron Limited Vancouver, BC Canada Immuron Inc New York USA Immuron Global HQ Melbourne Australia Our
Slide 7: Travelan continued strong sales growth
7 Travelan® continued strong sales growth Global + FY2025 AUD$7.3 million up 49% on prior year + FY2026 Q1 AUD$2.0 million up 34% on FY2025 Q1 Australia + FY2025 AUD$5.2 million up 40% on prior year + FY2026 AUD$1.6 million up 52% on FY2025 Q1 North America + FY2025 AUD$2.0 million up 76% on prior y
Slide 8: Expansion of Travelan Distribution
EXPANSION OF TRAVELAN® DISTRIBUTION 8
Slide 9: 2. Clinical Development Program
2. CLINICAL DEVELOPMENT PROGRAM
Slide 10: Status of product portfolio and key milestones
10 Anticipated Dates Current Status Collaborator or Funding Source Registration Phase 3 Phase 2 Phase 1 Preclinical Peak U.S. sales Compound Indication 1H 2026 2H 2025 Topline Data 100% of 851 participants recruited Uniformed Services University US$ 102 m Travelan® Traveller’s Diarrhoea End of Phase
Slide 11: 3. Upcoming Milestones & Outlook
3. UPCOMING MILESTONES & OUTLOOK
Slide 12: Upcoming Milestones & Outlook
12 Upcoming Milestones & Outlook Commercial + Continued quarter on quarter growth of Travelan® from growth drivers + Planned growth in profitability 1 of Hyperimmune products net of planned increased investment in selling & marketing Clinical IMM - 124E (Travelan®): Traveller’s Diarrhoea + IMM - 124
Slide 13: Scientific references
13 Scientific references Travelan® (IMM - 124E) Scandinavian Journal of Gastroenterology, 46:7 - 8, 862 - 868, DOI: 10.3109/00365521.2011.574726 Travelan® has been shown to reduce both the incidence and severity of ETEC - induced diarrhea in up to 90% of volunteers Military Health System Research Sy
Slide 14: Contact Information
EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172 STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: